SVRA
Savara Inc.
$5.50
+$0.12(+2.23%)
58
Overall
50
Value
90
Tech
36
Quality
Market Cap
$686.16M
Volume
4.76M
52W Range
$1.98 - $7.01
Target Price
$10.94
Company Overview
| Mkt Cap | $686.16M | Price | $5.50 |
| Volume | 4.76M | Change | +2.23% |
| P/E Ratio | -5.8 | Open | $5.51 |
| Revenue | -- | Prev Close | $5.38 |
| Net Income | $-118.8M | 52W Range | $1.98 - $7.01 |
| Div Yield | N/A | Target | $10.94 |
| Overall | 58 | Value | 50 |
| Quality | 36 | Technical | 90 |
No chart data available
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)
Christine Brown•5 days ago
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)
Christine Brown•5 days ago
Savara Expands Share Capital and Updates Executive Leadership
TipRanks Auto-Generated Newsdesk•12 days ago
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GSK) and Savara (SVRA)
Catie Powers•22 days ago
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)
Howard Kim•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SVRA | $5.50 | +2.2% | 4.76M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |